Physician profile
Amy C Bales
NPI 1255313540
$6,689.43
in general payments reported to CMS, 2019-2025
31 companies · $635 in 2025
The $635 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $859 · 2021: $1,380 · 2022: $1,011 · 2023: $900 · 2024: $888 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,422.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,306.70 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $900.80 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.22 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $512.65 | 2019-2025 | Wainua, Farxiga |
| Amgen INC. | $440.06 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $389.30 | 2019-2024 | Lifevest |
| Pfizer INC. | $358.56 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $328.70 | 2021-2024 | Verquvo |
| Chiesi USA, INC. | $260.80 | 2021-2025 | Cleviprex, Kengreal |
| Boston Scientific Corporation | $208.09 | 2022-2025 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $197.51 | 2020-2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $139.58 | 2019-2024 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $136.56 | 2020-2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $113.66 | 2019 | |
| Novo Nordisk INC | $94.79 | 2021-2025 | Wegovy, Ozempic |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $87.73 | 2021-2023 | Arcalyst |
| Lundbeck LLC | $83.89 | 2019-2020 | |
| Abbott Laboratories | $82.82 | 2020 | |
| Amarin Pharma, INC. | $80.42 | 2019-2022 | |
| Scpharmaceuticals INC. | $79.64 | 2023-2024 | |
| Gilead Sciences, INC. | $69.42 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $68.11 | 2019 | |
| Edwards Lifesciences Corporation | $48.51 | 2020 | |
| Itamar Medical INC | $28.38 | 2024 | Watchpatone |
| Lexicon Pharmaceuticals, INC. | $26.56 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $23.24 | 2022 | |
| Astellas Pharma US INC | $18.57 | 2019 | |
| Cardiovascular Systems INC. | $18.30 | 2020 | |
| W. L. Gore & Associates, INC. | $18.08 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.17 | 2021 | |
| Hikma Pharmaceuticals USA | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Bales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.